Gilead BD head Bender takes top job at pediatric cancer start-up Day One

With ex-Gilead BD head Jeremy Bender on board as CEO, Canaan-incubated pediatric cancer company Day One aims to expand its in-licensed pipeline and explore partnering opportunities with larger companies.

“My background complements both of those elements,” Bender told BioCentury, adding that his past roles gave him a bird's-eye view of oncology opportunities across industry...